Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Operations (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Cash from Operations for 16 consecutive years, with 233729.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 397.8% year-over-year to 233729.0, compared with a TTM value of 201107.0 through Sep 2025, up 127.66%, and an annual FY2024 reading of 500000.0, up 28.54% over the prior year.
  • Cash from Operations was 233729.0 for Q3 2025 at China Pharma Holdings, down from 287822.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1007286.0 in Q3 2023 and bottomed at 1468214.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 98042.0, with a median of 72726.0 recorded in 2024.
  • The sharpest move saw Cash from Operations surged 1017.6% in 2024, then plummeted 397.8% in 2025.
  • Year by year, Cash from Operations stood at 198112.0 in 2021, then surged by 395.08% to 584594.0 in 2022, then crashed by 103.82% to 22323.0 in 2023, then soared by 1017.6% to 204836.0 in 2024, then crashed by 214.11% to 233729.0 in 2025.
  • Business Quant data shows Cash from Operations for CPHI at 233729.0 in Q3 2025, 287822.0 in Q2 2025, and 57822.0 in Q1 2025.